Biomarker discovery and compound evaluation using two-hybrid proteomic systems.
Many proteomic technologies require a heavy investment in expertise and technology, which place these approaches beyond many labs and small companies. However, proteomic approaches are ideal for pilot experiments, identifying relevant biomarkers and protein pathways for development or analysis of therapeutic compounds. The two-hybrid proteomic systems are available and affordable to most researchers, requiring little more than standard microbiological equipment. The screens rapidly generate data, identifying protein interactions that can be used to construct small local protein networks. Using data from large-scale projects, these small local protein networks can be used to identify the larger cellular pathways that are being affected by therapeutic compounds in the screen. The foundation for the two-hybrid proteomic systems are commercially available, as are high quality cDNA libraries. The straightforwardness of the two-hybrid proteomic system allows smaller groups to focus their resources on critical cellular pathways and molecular targets by taking advantage of a trusted molecular assay and an ever growing set of postgenomic era databases.